<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04188418</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0701</org_study_id>
    <secondary_id>NCI-2019-07529</secondary_id>
    <secondary_id>2019-0701</secondary_id>
    <secondary_id>R01CA231471</secondary_id>
    <nct_id>NCT04188418</nct_id>
  </id_info>
  <brief_title>Fentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients</brief_title>
  <official_title>Efficacy and Safety of Rapid-Onset Opioids for Exertional Dyspnea in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies fentanyl buccal tablet or morphine to see how well it works&#xD;
      compared to a placebo in controlling shortness of breath during or after physical activity in&#xD;
      cancer patients. Fentanyl sublingual tablet and morphine are opioids normally used to control&#xD;
      pain that may also help to prevent or control shortness of breath during or after physical&#xD;
      activity in cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To compare the effect of prophylactic fentanyl buccal tablet (FBT), morphine sulfate, and&#xD;
      placebo on the increase in the intensity of exertional dyspnea (0-10 point modified Borg&#xD;
      scale) measured before versus at the end of a shuttle walk test (SWT).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To compare the effects of prophylactic FBT, morphine sulfate, and placebo on SWT distance&#xD;
      and dyspnea unpleasantness, average daily dyspnea (intensity and unpleasantness, oxygen cost&#xD;
      diagram), personalized daily activity (ability to complete activity), personalized dyspnea&#xD;
      response, symptom burden (Edmonton Symptom Assessment System [ESAS]), quality of life&#xD;
      (EuroQol-5 Dimension-5 Level [EQ-5D-5L]), and dyspnea severity and functional impairment&#xD;
      based on the Patient Reported Outcomes Measurement Information System (PROMIS) dyspnea&#xD;
      instruments.&#xD;
&#xD;
      II. To explore the effects of prophylactic FBT, morphine sulfate, and placebo on&#xD;
      neurocognitive function, addictive potential (Drug Effects Questionnaire), adverse effects&#xD;
      (Common Terminology Criteria for Adverse Events [CTCAE], Patient-Reported Outcomes version of&#xD;
      CTCAE [PRO-CTCAE]), and pattern of opioid use.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 3 groups.&#xD;
&#xD;
      GROUP I: Patients complete shuttle walk test on days 1, 5, 8, 12, 15, and 19. Patients also&#xD;
      receive FBT sublingually daily on days 6-19.&#xD;
&#xD;
      GROUP II: Patients complete shuttle walk test on days 1, 5, 8, 12, 15, and 19. Patients also&#xD;
      receive morphine orally (PO) daily on days 6-19.&#xD;
&#xD;
      GROUP III: Patients complete shuttle walk test on days 1, 5, 8, 12, 15, and 19. Patients also&#xD;
      receive placebo (sublingually or PO) daily on days 6-19.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in modified Borg scale dyspnea intensity before and after the Shuttle Walk Test (SWT)</measure>
    <time_frame>Days 5, 8, 12, 15, and 19</time_frame>
    <description>Will first determine whether the three treatment groups are different; if so, will test the three pairwise comparisons with intention-to-treat analyses. Repeated-measures analysis of variance (ANOVA) will be implemented using linear mixed effects models with the difference in intervention period SWT modified Borg scale dyspnea intensity before and after SWT as the response variable and the treatment group and observation period SWT measures as predictor variables.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SWT distance</measure>
    <time_frame>Days 5, 8, 12, 15, and 19</time_frame>
    <description>Will be analyzed using linear mixed effects models similar to the primary analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea unpleasantness</measure>
    <time_frame>Days 5, 8, 12, 15, and 19</time_frame>
    <description>Will be analyzed using linear mixed effects models similar to the primary analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily dyspnea intensity and unpleasantness</measure>
    <time_frame>Days 1-19</time_frame>
    <description>Will be analyzed using linear mixed effects models similar to the primary analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Personalized daily activity</measure>
    <time_frame>Days 1-4, 6-7, 9-11, 13-14, and 16-18</time_frame>
    <description>Will be analyzed using linear mixed effects models similar to the primary analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen cost diagram</measure>
    <time_frame>Days 1-19</time_frame>
    <description>Will be analyzed using linear mixed effects models similar to the primary analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom burden Questionnaires</measure>
    <time_frame>Days 1-19</time_frame>
    <description>Will be measured by the Edmonton Symptom Assessment System and analyzed using linear mixed effects models similar to the primary analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life Questionnaires</measure>
    <time_frame>Days 1-19</time_frame>
    <description>Will be measured by the EuroQol-5 Dimension-5 Level Questionnaire and analyzed using linear mixed effects models similar to the primary analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive function</measure>
    <time_frame>Up to day 19</time_frame>
    <description>Will perform paired t-test or ANOVA if the data are normally distributed and the Wilcoxon rank-sum test or Kruskal-Wallis if the data are non-normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Addictive potential</measure>
    <time_frame>Up to day 19</time_frame>
    <description>Will be measured by the Drug Effects Questionnaire. Will perform paired t-test or ANOVA if the data are normally distributed and the Wilcoxon rank-sum test or Kruskal-Wallis if the data are non-normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, severity, and interference of adverse effects</measure>
    <time_frame>Up to day 19</time_frame>
    <description>Will be measured by the Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE). Will perform paired t-test or ANOVA if the data are normally distributed and the Wilcoxon rank-sum test or Kruskal-Wallis if the data are non-normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total opioid dose</measure>
    <time_frame>Up to day 19</time_frame>
    <description>Will perform paired t-test or ANOVA if the data are normally distributed and the Wilcoxon rank-sum test or Kruskal-Wallis if the data are non-normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of rescue doses per day</measure>
    <time_frame>Up to day 19</time_frame>
    <description>Will perform paired t-test or ANOVA if the data are normally distributed and the Wilcoxon rank-sum test or Kruskal-Wallis if the data are non-normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea severity and functional impairment</measure>
    <time_frame>Day 1, 5, 12, 19</time_frame>
    <description>Will be measured using the Patient Reported Outcomes Measurement Information System (PROMIS) dyspnea instruments.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Malignant Solid Neoplasm</condition>
  <arm_group>
    <arm_group_label>Group I (shuttle walk test, FBT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients complete shuttle walk test on days 1, 5, 8, 12, 15, and 19. Patients also receive FBT sublingually daily on days 6-19.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (shuttle walk test, morphine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients complete shuttle walk test on days 1, 5, 8, 12, 15, and 19. Patients also receive morphine PO daily on days 6-19.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III (shuttle walk test, placebo)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients complete shuttle walk test on days 1, 5, 8, 12, 15, and 19. Patients also receive placebo (sublingually or PO) daily on days 6-19.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl Citrate Buccal Tablet</intervention_name>
    <description>Given transmucosally</description>
    <arm_group_label>Group I (shuttle walk test, FBT)</arm_group_label>
    <other_name>Fentora</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group II (shuttle walk test, morphine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physical Performance Testing</intervention_name>
    <description>Complete shuttle walk test</description>
    <arm_group_label>Group I (shuttle walk test, FBT)</arm_group_label>
    <arm_group_label>Group II (shuttle walk test, morphine)</arm_group_label>
    <arm_group_label>Group III (shuttle walk test, placebo)</arm_group_label>
    <other_name>Physical Fitness Testing</other_name>
    <other_name>Physical Function Testing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Administration</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group III (shuttle walk test, placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Group I (shuttle walk test, FBT)</arm_group_label>
    <arm_group_label>Group II (shuttle walk test, morphine)</arm_group_label>
    <arm_group_label>Group III (shuttle walk test, placebo)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Group I (shuttle walk test, FBT)</arm_group_label>
    <arm_group_label>Group II (shuttle walk test, morphine)</arm_group_label>
    <arm_group_label>Group III (shuttle walk test, placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of cancer with evidence of active disease&#xD;
&#xD;
          -  Dyspnea on exertion with an average intensity level &gt;= 4/10 on a modified Borg scale&#xD;
&#xD;
          -  Outpatient at participating centers&#xD;
&#xD;
          -  Ambulatory and able to walk, with or without walking aid&#xD;
&#xD;
          -  On strong opioids with morphine equivalent daily dose (MEDD) of 60-370 mg for &gt;= 1&#xD;
             week (wk), with stable (i.e. +/- 30%) regular dose over the last 3 days (d)&#xD;
&#xD;
          -  Karnofsky performance status &gt;= 40%&#xD;
&#xD;
          -  Age &gt;= 18 years (yrs)&#xD;
&#xD;
          -  Able to complete study assessments&#xD;
&#xD;
          -  Able to speak English or Spanish&#xD;
&#xD;
          -  Reside within 50 miles of participating centers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dyspnea at rest &gt;= 7/10 on modified Borg scale at enrollment&#xD;
&#xD;
          -  Supplemental oxygen requirement &gt; 6 L/min&#xD;
&#xD;
          -  Delirium (i.e. Memorial Delirium Assessment Scale &gt;= 13)&#xD;
&#xD;
          -  History of unstable angina or myocardial infarction 1 month prior to enrollment&#xD;
&#xD;
          -  Resting heart rate &gt; 120 beats/min at enrollment&#xD;
&#xD;
          -  Systolic pressure &gt; 180 mmHg or diastolic pressure &gt; 100 mmHg at enrollment&#xD;
&#xD;
          -  History of substance use disorder or abnormal urinary drug screen within the past&#xD;
             year, or at risk of opioid abuse as determined by Screener and Opioid Assessment for&#xD;
             Patients with Pain (SOAPP14) &gt;= 7&#xD;
&#xD;
          -  History of or known allergy to fentanyl or morphine sulfate&#xD;
&#xD;
          -  Currently prescribed benzodiazepines&#xD;
&#xD;
          -  Severe anemia (Hemoglobin [Hb] &lt; 7 g/L) if documented in the last month and not&#xD;
             corrected prior to study enrollment&#xD;
&#xD;
          -  Bilirubin &gt;=5 x upper limit of normal if documented in the last month and not lowered&#xD;
             to &lt; 5 x normal prior to enrollment&#xD;
&#xD;
          -  Diagnosis of acute pulmonary embolism within past 2 weeks&#xD;
&#xD;
          -  Diagnosis of pulmonary hypertension&#xD;
&#xD;
          -  Diagnosis of malignant pleural effusion with therapeutic thoracentesis expected in the&#xD;
             next 2 weeks&#xD;
&#xD;
          -  Unwilling to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hui</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Hui</last_name>
    <phone>713-792-6085</phone>
    <email>dhui@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Hui</last_name>
      <phone>713-792-6085</phone>
      <email>dhui@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>David Hui</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>December 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2019</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

